ABSTRACT-We investigated the combined effects of alendronate and 1a-hydroxyvitamin D3 (1a(OH)D3) on the bone mass and strength in aged ovariectomized rats and compared them with those of single treatments. Forty-week-old female rats underwent ovariectomy or sham operation, and after 15 weeks, ovariectomized rats were daily administered vehicle alone, alendronate (0.2 or 1.0 mg /kg, p.o.), 1a(OH)D 3 (0.02 mg/kg, p.o.), or the combinations of 0.2 or 1.0 mg /kg of alendronate and 1a(OH)D 3 . After 12 weeks, the groups receiving combined treatments had significantly increased bone density and mechanical strength of the 4th lumbar vertebral body and the midfemur compared to the vehicle-treated group, and the effects were almost equal to or slightly less than the addition of those of the respective single treatments. The increase in mechanical strength was proportional to that in bone mineral density, suggesting that the stimulatory effects of these treatments on bone strength are ascribable primarily to those on bone mass. Analyses of histology, computed tomography, and biochemical markers confirmed the strong effect of the combined treatment on trabecular bone in particular, which was associated with increased trabecular number and decreased bone turnover. We propose that the combination of daily alendronate and 1a (OH)D 3 is clinically promising as a curative treatment of established postmenopausal osteoporosis.Keywords: Combined treatment, Alendronate, 1a -Hydroxyvitamin D3, Ovariectomy, Osteoporosis Estrogen deficiency after menopause is associated with bone loss leading to fractures that constitute a serious health problem in many countries (1). Many bone-sparing drugs have successively been developed for the treatment of postmenopausal osteoporosis (2). However, the effects of the combined treatments of these drugs have not been well investigated despite the fact that postmenopausal osteoporosis is frequently treated with combination therapy.Bisphosphonates, potent anti-resorptive agents, are known to be one of the most reliable and prevalent drugs in osteoporosis treatment. Alendronate (sodium 4-amino-1-hydroxybutilidene-1,1-bisphosphonate trihydrate), an aminobisphosphonate, is well known as a potent inhibitor of osteoclastic bone resorption (3 -5). The efficacy of bisphosphonates has been demonstrated in osteoporosis (6 -8) as well as in various other metabolic bone disorders such as Paget's disease (9) and hypercalcemia of malignancy (10). Alendronate has also been reported to increase the bone mass and strength in ovariectomized (OVX) rats (11 -13). The modes of action of alendronate include suppression of the differentiation of osteoclast precursors (14 -16) and the activation of mature osteoclast function (17), resulting in the decrease in bone turnover. Recent studies on its molecular mechanism show that aminobisphosphonates such as alendronate can inhibit enzymes of the mevalonate pathway (18).Vitamin D and vitamin D derivatives may also have a role in osteoporosis (19), and the activated form of vitam...